anti-CD3/anti-CD20 bispecific T-cell engager Y-Body (Wuhan YZY Biopharma)

N/A

Report date: 2026/03/19 16:58:29

Base Information

Drug Nameanti-CD3/anti-CD20 bispecific T-cell engager Y-Body (Wuhan YZY Biopharma)

Drug Alias Nameanti-CD20/anti-CD3 bispecific antibody (Wuhan YZY Biopharma)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesWuhan Yzy Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWuhan Yzy Biopharma Co Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A